[Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas].

Q4 Medicine

Arkhiv patologii Pub Date : 2025-01-01 DOI:10.17116/patol20258702111

S N Nered, R O Torosyan, N A Kozlov, H Sun, I G Avdyukhin, P V Kononets, I S Stilidi

{"title":"[Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas].","authors":"S N Nered, R O Torosyan, N A Kozlov, H Sun, I G Avdyukhin, P V Kononets, I S Stilidi","doi":"10.17116/patol20258702111","DOIUrl":null,"url":null,"abstract":"Gastric cancer (GC) is a heterogeneous tumor with various molecular changes. An active search for molecular markers is crucial to determine the effectiveness of drug treatment and prognosis of the disease. Several biomarkers have the greatest clinical significance: HER2, MSI / dMMR, PD-L1 (CPS), EBV and Claudin 18.Objective: To study the frequency of HER2, MSI / dMMR and PD-L1 (CPS) in patients with operable GC depending on the tumor type according to P. Lauren.Material and methods: The study included 600 patients with GC who underwent radical surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology from 2018 to 2023.Results: In the study, the proportion of diffuse GC was 21.5% (120/600). HER2 overexpression was found in 5.2% (5/96) of cases with diffuse GC, 20.4% (37/181) of cases with intestinal GC, 10.1% (7/69) of cases with mixed GC (p=0.0029). The incidence of MSI was 3.3% (4/120) of cases with diffuse GC, 11.2% (28/251) of cases with intestinal GC, 7.3% (7/97) of cases with mixed GC (p=0.0378). PD-L1 expression (CPS> 1) was found in 42.3% (11/26) of cases with diffuse GC, 59.4% (35/59) of cases with intestinal GC, 27.3% (9/33) of cases with mixed GC (p=0.006). In poorly cohesive/signet ring cell cancer MSI occurred in 2.5% (2/79) of cases; HER2 overexpression - in 2.9% (2/68) of cases; PD-L1 (CPS> 1) - in 42.1% (8/19) of cases.Conclusion: Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":"87 2","pages":"11-17"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arkhiv patologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/patol20258702111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric cancer (GC) is a heterogeneous tumor with various molecular changes. An active search for molecular markers is crucial to determine the effectiveness of drug treatment and prognosis of the disease. Several biomarkers have the greatest clinical significance: HER2, MSI / dMMR, PD-L1 (CPS), EBV and Claudin 18.

Objective: To study the frequency of HER2, MSI / dMMR and PD-L1 (CPS) in patients with operable GC depending on the tumor type according to P. Lauren.

Material and methods: The study included 600 patients with GC who underwent radical surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology from 2018 to 2023.

Results: In the study, the proportion of diffuse GC was 21.5% (120/600). HER2 overexpression was found in 5.2% (5/96) of cases with diffuse GC, 20.4% (37/181) of cases with intestinal GC, 10.1% (7/69) of cases with mixed GC (p=0.0029). The incidence of MSI was 3.3% (4/120) of cases with diffuse GC, 11.2% (28/251) of cases with intestinal GC, 7.3% (7/97) of cases with mixed GC (p=0.0378). PD-L1 expression (CPS> 1) was found in 42.3% (11/26) of cases with diffuse GC, 59.4% (35/59) of cases with intestinal GC, 27.3% (9/33) of cases with mixed GC (p=0.006). In poorly cohesive/signet ring cell cancer MSI occurred in 2.5% (2/79) of cases; HER2 overexpression - in 2.9% (2/68) of cases; PD-L1 (CPS> 1) - in 42.1% (8/19) of cases.

Conclusion: Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.

查看原文本刊更多论文

[MSI, PD-L1 (CPS)， HER2在低黏性胃癌中的频率]。

胃癌是一种具有多种分子变化的异质性肿瘤。积极寻找分子标记对于确定药物治疗的有效性和疾病的预后至关重要。有几个生物标志物具有最大的临床意义：HER2、MSI / dMMR、PD-L1 （CPS）、EBV和Claudin 18。目的：研究可手术胃癌患者中HER2、MSI / dMMR和PD-L1 （CPS）在不同肿瘤类型中的表达频率。材料和方法：本研究纳入了2018年至2023年在N.N. Blokhin国家肿瘤医学研究中心接受根治性手术治疗的600例胃癌患者。结果：弥漫性气相色谱占21.5%（120/600）。HER2过表达在弥漫型胃癌中占5.2%(5/96)，在肠型胃癌中占20.4%(37/181)，在混合型胃癌中占10.1% (7/69)（p=0.0029）。弥漫性胃癌的MSI发生率为3.3%(4/120)，肠性胃癌为11.2%(28/251)，混合性胃癌为7.3% (7/97)（p=0.0378）。弥漫性胃癌中有42.3%（11/26）、肠性胃癌中有59.4%（35/59）、混合性胃癌中有27.3%（9/33）表达PD-L1 (CPS> 1) （p=0.006）。在低凝聚力/印戒细胞癌中，2.5%（2/79）的病例发生MSI；HER2过表达：2.9%（2/68）的病例；42.1%（8/19）病例PD-L1 （CPS bbb1）阳性。结论：我们的研究表明，在弥漫性和低粘性/印戒细胞GC中，上述临床意义的肿瘤生物标志物的发生频率低于肠道/混合GC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arkhiv patologii Medicine-Pathology and Forensic Medicine

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The journal deals with original investigations on pressing problems of general pathology and pathologic anatomy, newest research methods, major issues of the theory and practice as well as problems of experimental, comparative and geographic pathology. To inform readers latest achievements of Russian and foreign medicine the journal regularly publishes editorial and survey articles, reviews of the most interesting Russian and foreign books on pathologic anatomy, new data on modern methods of investigation (histochemistry, electron microscopy, autoradiography, etc.), about problems of teaching, articles on the history of pathological anatomy development both in Russia and abroad.